← All trials
NCT04082182
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 26, 2019
- Primary completion
- Sep 24, 2020
- Completion date
- Dec 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 6
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ghent UniversityLead sponsor
- Ghent UniversityOverall official - principal investigator
- Ghent UniversityReponsible party - principal investigator
- Kom Op Tegen KankerCollaborator
- Ghent UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.